OBJECTIVE: @entity1 with @entity3119 ( @entity3119 ) often only partially respond to @entity750 reuptake inhibitors (SRIs). In such cases, American Psychiatric Association practice guidelines suggest augmenting SRIs with cognitive-behavioral therapy consisting of exposure and ritual prevention (EX/RP) or antipsychotic medication (i.e., @entity1090 ). We examined moderators and predictors of these 2 augmentation strategies. METHOD: Data came from a randomized controlled trial that compared adding EX/RP or @entity1090 to SRIs in adults with @entity3119 . @entity1 entered the study on a stable SRI dosage and were randomized to EX/RP (N = 40), @entity1090 (N = 40), or placebo (N = 20). Data were analyzed using multilevel modeling. RESULTS: Pretreatment @entity3119 severity, age, and @entity308 were significant moderators. Although @entity3119 severity was unrelated to EX/RP response, individuals with more severe @entity3119 had poorer outcomes and slower improvement with @entity1090 . Increasing age predicted better response to @entity1090 , but not EX/RP. Increased @entity308 predicted poorer response to placebo, but not EX/RP or @entity1090 . Poorer functioning predicted worse outcome across all 3 conditions. Together, these moderators and predictor accounted for 33% of the variance in outcomes, above and beyond the 30.8% accounted for by treatment condition. CONCLUSIONS: SRI augmentation with EX/RP was more effective than @entity1090 across all of the demographic and clinical variables tested. EX/RP's superiority over @entity1090 increased with baseline @entity3119 severity and with younger age. These data indicate that EX/RP should be the recommended SRI augmentation strategy, even for severe @entity3119 . What determines the degree of EX/RP response in individual @entity1 deserves further study. (PsycINFO Database Record

Augmenting @entity750 reuptake inhibitors in XXXX : What moderates improvement?

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity308 :: ('MESH:D003866', 'Disease') :: ['depression'] @entity750 :: ('MESH:D012701', 'Chemical') :: ['serotonin'] @entity3119 :: ('MESH:D009771', 'Disease') :: ['obsessive-compulsive disorder', 'OCD'] @entity1090 :: ('MESH:D018967', 'Chemical') :: ['risperidone']
@entity3119 :: (MESH:D009771,Disease) :: ['obsessive-compulsive disorder']
